Merck’s Hep C Meds Work Well in Treatment-Experienced People
The Phase II C-SALVAGE trial included 79 people who had failed a previous regimen of interferon, ribavirin and either Olysio (simeprevir), Incivek (telaprevir) or Victrelis (boceprevir). Results were presented at the 50th International Liver Congress in Vienna, Austria.
The Phase II C-SALVAGE trial included 79 people who had failed a previous regimen of interferon, ribavirin and either Olysio (simeprevir), Incivek (telaprevir) or Victrelis (boceprevir). Results were presented at the 50th International Liver Congress in Vienna, Austria.